# GSK Plc files to broaden Arexvy use in Japan

- Link: https://www.directorstalkinterviews.com/gsk-plc-files-to-broaden-arexvy-use-in-japan/4121203315
- Published: 2025-06-20T07:32:31+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE: GSK) has announced that Japan’s Ministry of Health, Labour and Welfare(
MHLW) has accepted the company’s regulatory application to expand the use of its
adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults
aged 18-49 at increased risk of severe RSV disease. _Arexvy_ was the first vaccine
approved in Japan for adults aged 60 years and older for the prevention of RSV disease,
and for those aged 50 years and older at increased risk for severe RSV disease.

RSV is a common, contagious virus affecting the lungs and breathing passages impacting
an estimated 64 million people of all ages globally every year.^([1]) RSV can exacerbate
certain medical conditions, and lead to severe illness resulting in hospitalisation
and even death^([2],[3],[4]).

This regulatory submission is supported by positive results from phase IIIb trial
NCT06389487^([5]) which showed a non-inferior immune response in adults aged 18-
49 at increased risk for RSV-LRTD due to certain underlying medical conditions, 
to that observed in adults aged 60 and above. The safety and reactogenicity data
were consistent with results from the phase III programme that supported the initial
approval of the vaccine in Japan.

GSK is the first company to seek regulatory approval for the vaccine to help protect
adults aged 18-49 at increased risk of severe RSV disease in Japan. Regulatory submissions
to expand the indications for the RSV vaccine continue in other geographies including
the US and Europe.

**About _Arexvy_**

Respiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein
F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined 
with GSK’s proprietary AS01_(E) adjuvant.

The MHLW has approved GSK’s RSV vaccine for the prevention of RSV (respiratory syncytial
virus) disease for adults aged 60 years and above and adults aged 50 and older who
are considered at increased risk of severe RSV disease. The use of this vaccine 
should be in accordance with official recommendations. As with any vaccine, a protective
immune response may not be elicited in all vaccinees.

The GSK proprietary AS01 adjuvant system contains STIMULON QS-21 adjuvant licensed
from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. STIMULON is a trademark
of SaponiQx Inc., a subsidiary of Agenus.

**About the NCT06389487 trial**

NCT06389487 is a phase IIIb open-label study to evaluate the non-inferiority of 
the immune response and to evaluate the safety of GSK’s RSV vaccine in adults aged
18-49 at increased risk for RSV disease (n=426) compared to adults aged 60 and older(
n=429). An additional cohort of 603 participants aged 18-49 were followed up for
adverse events separate to safety follow up of the initial cohort. 1,458 participants
were enrolled across 52 locations in 6 countries, including 4 sites in Japan.

The trial’s co-primary endpoints were RSV-A and RSV-B neutralisation titers expressed
as mean geometric titer ratio (relative to older adults over adults at increased
risk) and sero-response rate in RSV-A and RSV-B neutralising titers one month post
vaccine administration. There were also safety and immunogenicity secondary endpoints.

[1] National Institute of Allergy and Infectious Diseases, Respiratory Syncytial
Virus (RSV). Available at: https://www.niaid.nih.gov/diseases-conditions/respiratory-
syncytial-virus-rsv – last accessed: June 2025

[2] Falsey, AR et al. Respiratory syncytial virus infection in elderly and high-
risk adults, in New Engl J Med 2005; 352:1749-59

[3] Osei-Yeboah, R et al. Respiratory Syncytial Virus-Associated Hospitalization
in Adults with Comorbidities in 2 European Countries: A Modeling Study. J Infect
Dis; 2024; 229 (suppl 1): S70-S77

[4] Atamna A, Babich T, Froimovici D, Yahav D, Sorek N, Ben-Zvi H, Leibovici L, 
Bishara J, Avni T. Morbidity and mortality of respiratory syncytial virus infection
in hospitalized adults: Comparison with seasonal influenza. Int J Infect Dis. 2021
Feb;103:489-493. doi: 10.1016/j.ijid.2020.11.185.

[5] Clinicaltrials.gov, “A Study on the Immune Response and Safety of Vaccine Against
Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased
Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years 
of Age and Above” – available at: https://clinicaltrials.gov/study/NCT06389487

Share on:
